Csenge Advisory Group Makes New $428,000 Investment in Oscar Health, Inc. $OSCR

Csenge Advisory Group purchased a new position in shares of Oscar Health, Inc. (NYSE:OSCR) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 29,753 shares of the company’s stock, valued at approximately $428,000.

Other large investors have also recently bought and sold shares of the company. Quarry LP grew its position in Oscar Health by 439.8% in the third quarter. Quarry LP now owns 1,803 shares of the company’s stock valued at $34,000 after acquiring an additional 1,469 shares during the period. Tsfg LLC bought a new stake in Oscar Health in the third quarter valued at $38,000. Jones Financial Companies Lllp grew its position in Oscar Health by 7,473.3% in the first quarter. Jones Financial Companies Lllp now owns 2,272 shares of the company’s stock valued at $30,000 after acquiring an additional 2,242 shares during the period. Strs Ohio bought a new stake in Oscar Health in the first quarter valued at $30,000. Finally, Fifth Third Bancorp grew its position in Oscar Health by 148.7% in the fourth quarter. Fifth Third Bancorp now owns 2,363 shares of the company’s stock valued at $34,000 after acquiring an additional 1,413 shares during the period. 75.70% of the stock is currently owned by institutional investors.

Oscar Health Price Performance

Shares of OSCR stock opened at $22.11 on Friday. The stock’s fifty day moving average is $16.30 and its 200-day moving average is $15.55. The company has a debt-to-equity ratio of 0.26, a quick ratio of 1.11 and a current ratio of 1.11. The stock has a market capitalization of $6.67 billion, a PE ratio of -37.48, a PEG ratio of 1.64 and a beta of 2.34. Oscar Health, Inc. has a 52 week low of $10.69 and a 52 week high of $25.58.

Oscar Health (NYSE:OSCR) last announced its earnings results on Wednesday, May 6th. The company reported $2.07 EPS for the quarter, topping the consensus estimate of $1.11 by $0.96. The company had revenue of $4.65 billion for the quarter, compared to analysts’ expectations of $4.90 billion. Oscar Health had a negative return on equity of 3.26% and a negative net margin of 0.30%.The business’s revenue for the quarter was up 52.6% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.92 earnings per share. Equities research analysts expect that Oscar Health, Inc. will post 0.47 EPS for the current fiscal year.

Insider Buying and Selling at Oscar Health

In other news, CFO Richard Scott Blackley sold 100,000 shares of the company’s stock in a transaction on Thursday, May 14th. The stock was sold at an average price of $23.16, for a total transaction of $2,316,000.00. Following the transaction, the chief financial officer owned 1,216,660 shares of the company’s stock, valued at $28,177,845.60. This represents a 7.59% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Mark T. Bertolini purchased 1,000,000 shares of the business’s stock in a transaction dated Monday, April 6th. The shares were purchased at an average cost of $11.92 per share, for a total transaction of $11,920,000.00. Following the purchase, the chief executive officer directly owned 10,196,876 shares of the company’s stock, valued at $121,546,761.92. This trade represents a 10.87% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Corporate insiders own 24.39% of the company’s stock.

Wall Street Analysts Forecast Growth

OSCR has been the topic of a number of analyst reports. Robert W. Baird upped their price target on Oscar Health from $15.00 to $19.00 and gave the company a “neutral” rating in a research report on Thursday, May 7th. Weiss Ratings reiterated a “sell (d)” rating on shares of Oscar Health in a research report on Tuesday, April 21st. Jefferies Financial Group upgraded Oscar Health from an “underperform” rating to a “hold” rating and upped their price target for the company from $10.00 to $16.00 in a research report on Monday, April 20th. Wall Street Zen upgraded Oscar Health from a “hold” rating to a “strong-buy” rating in a report on Saturday, May 9th. Finally, Wolfe Research started coverage on Oscar Health in a report on Tuesday, May 5th. They set a “peer perform” rating on the stock. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, seven have issued a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $18.22.

About Oscar Health

Oscar Health, trading on the New York Stock Exchange under the ticker OSCR, is a technology-driven health insurance company headquartered in New York, New York. Founded in 2012 by Mario Schlosser, Joshua Kushner and Kevin Nazemi, the company was built with the goal of simplifying healthcare coverage and enhancing member experience. Oscar leverages a proprietary digital platform to streamline plan enrollment, claims administration and member support, distinguishing itself in the individual, family and small group insurance markets.

The company’s primary products include on-exchange individual and family medical plans under the Affordable Care Act, off-exchange plans, as well as Medicare Advantage offerings.